The Neurodegenerative Disease Market is entering an important phase of transformation as pharmaceutical innovation, advanced diagnostics, aging populations, and disease-modifying therapies reshape neurological care. According to Market Research Future, the market reached USD 54.93 billion in 2025 and is projected to reach USD 112.72 billion by 2035, expanding at a CAGR of 7.5% during the forecast period.

Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and Huntington's disease continue to create substantial healthcare needs worldwide. Increasing life expectancy and the growing elderly population are contributing to a larger patient pool, creating sustained demand for diagnosis, treatment, rehabilitation, and long-term disease management solutions.

One of the most significant developments in the market is the growing emphasis on disease-modifying treatments. Traditional neurological therapies have primarily focused on managing symptoms, while newer approaches are increasingly targeting underlying biological mechanisms. Monoclonal antibodies, gene therapies, cell therapies, and RNA-based therapeutics are expanding the range of treatment possibilities available to patients.

Alzheimer's disease remains the largest indication segment, accounting for 39.2% of market share in 2025. Parkinson's disease also represents a significant opportunity, with revenue of approximately USD 13.62 billion in 2025. Meanwhile, ALS is projected to be one of the fastest-growing indications, supported by genetically targeted treatments and advances in precision medicine.

Diagnostics are also becoming an important growth engine. Blood-based biomarkers, imaging technologies, neurological examinations, cerebrospinal fluid analysis, and electrophysiological testing are helping improve disease identification. The expansion of blood-based diagnostic technologies may make neurological assessment more accessible and reduce dependence on expensive or specialized procedures.

Regionally, North America dominated the market with a 39.4% revenue share in 2025. Strong pharmaceutical infrastructure, specialized neurological centers, advanced reimbursement systems, and high adoption of innovative therapies support regional leadership. Asia-Pacific is expected to experience the fastest growth, with a projected CAGR of 8.9% through 2035.

The competitive environment includes major companies such as Biogen, Eisai, Eli Lilly, AbbVie, Roche, Novartis, Teva, Lundbeck, UCB, Supernus Pharmaceuticals, Denali Therapeutics, and uniQure.

Overall, the neurodegenerative disease market presents substantial opportunities for pharmaceutical companies, biotechnology firms, diagnostic developers, healthcare providers, and investors. Continued innovation in disease modification, precision medicine, diagnostics, and home-based treatment delivery is expected to support market expansion through 2035.